The cytokine transforming growth factor-β (TGF-β) regulates the development and homeostasis of several tissue-resident macrophage populations, including microglia. TGF-β is not critical for microglia survival but is required for the maintenance of the microglia-specific homeostatic gene signature1,2. Under defined host conditions, circulating monocytes can compete for the microglial niche and give rise to long-lived monocyte-derived macrophages residing in the central nervous system (CNS)3,4,5. Whether monocytes require TGF-β for colonization of the microglial niche and maintenance of CNS integrity is unknown. We found that abrogation of TGF-β signaling in CX3CR1+ monocyte-derived macrophages led to rapid onset of a progressive and fatal demyelinating motor disease characterized by myelin-laden giant macrophages throughout the spinal cord. Tgfbr2-deficient macrophages were characterized by high expression of genes encoding proteins involved in antigen presentation, inflammation and phagocytosis. TGF-β is thus crucial for the functional integration of monocytes into the CNS microenvironment.
Access optionsAccess options
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Subscribe to Journal
Get full journal access for 1 year
only $18.75 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
We thank A. van Vollenhoven for flow cytometry. We thank the staff at AKM, particularly E. Qvist, for animal caretaking and M. Gustafsson for performing tail-vein injections. We thank A. Svensson, D. Sunnemark and A. Dahlstrand for help with slide scanning, performed at Offspring Biosciences, Södertälje. We thank M. Li (Sloan Kettering Institute) for Tgfbr2fl/fl mice and F. Wermeling (Karolinska Institutet) for CD45.1 mice. We acknowledge support from the Science for Life Laboratory, the National Genomics Infrastructure (NGI) and Uppmax for providing assistance in next-generation sequencing and computational infrastructure.
This work was supported by grants from the Swedish Alzheimer Foundation (Alzheimerfonden, AF-74004, R.A.H.), Swedish Research Council (Vetenskapsrådet, 2014-02087, R.A.H. and K2015-61X-20776-08-3, M.J.), Swedish Childhood Cancer Foundation (Barncancerfonden, PR2014-0154 and NCP2015-0064, X.-M.Z.), Åke Wibergs stiftelse (M14-0263, X.-M.Z.), Foundation of Swedish MS Research (MS Forskningsfonden, L.K.), Swedish Heart-Lung Foundation (Hjärt-Lungfonden, M.J.F. and D.F.J.K.), the Novo Nordisk Foundation (NNF15CC0018346, M.J.F. and D.F.J.K.), NIH-NINDS (1R01NS088137, O.B.), NIH-NIA (R01AG051812 and R01AG054672, O.B.), National Multiple Sclerosis Society (5092A1, O.B.) and Amyotrophic Lateral Sclerosis Association (ALSA2087, O.B.), and by a Nancy Davis Foundation Faculty Award (O.B.). X.-M.Z. was supported by a fellowship from the Swedish Childhood Cancer Foundation (Barncancerfonden, NC2014-0046, NBCNS). L.K. was supported by a fellowship from the Margaretha af Ugglas Foundation.
Integrated supplementary information
Supplementary Figure 1 Repopulation of microglia by peripheral myeloid cells in chimeric Cx3cr1CreER/+R26DTR/+ and Cx3cr1CreER/+R26DTA/+ mice.
(a) Gating strategy of CNS cells employed in the study. (b-c) Analysis of CNS, top panel gated on live, singlet and Ly6C–Ly6G– cells in (b) CD45.1→Cx3cr1CreER/+R26DTR/+ and (c) CD45.1→Cx3cr1CreER/+R26DTA/+ chimeras. Values in dot plots are mean±s.d. of (b) n=5 and 6 mice from two pooled experiments and (c) n=5 mice/group from one of two independent experiments.
Supplementary Figure 2 Lack of adaptive immunological changes in Cx3cr1CreER/+Tgfbr2fl/fl→DTA chimeras.
(a) Analysis of T cell (CD11b–CD45hiCD3+) and B cell (CD11b–CD45hiMHCII+) numbers in the brain and spinal cord of the indicated chimeras at day 20 after TAM. Lines in graphs represent mean values of n=3 and 4 mice. The experiment was performed once. (b) Analysis of proliferating T cells, CD4+FoxP3+ regulatory T cells and IFN-γ, IL-17 and TNF-α producing CD4+ T cells in the spleens of the indicated chimeras after onset of motor symptoms (day 20 after TAM). Values in plots are mean±s.d. of n=6 and 5 mice. The experiment was performed once.
Supplementary Figure 3 Analysis of lower motor neuron pathology and thalamic lesions in Cx3cr1CreER/+Tgfbr2fl/fl→DTA chimeras.
(a) Analysis of innervation of neuromuscular junctions in the tibialis anterior muscle of Tgfbr2fl/fl→DTA and Cx3cr1CreER/+Tgfbr2fl/fl→DTA chimeras. Innervation was quantified by assessing overlay of synaptic vesicle protein (SV2) and neurofilament (NF) 165 kDA staining with α-BTX labeled endplates. Positive control is tibials anterior muscle from SODG93A mice (day 140) illustrating complete denervation. Lines in graph are mean values of n = 4, 2, 3, 4 mice/group and at least 40 motor endplates/mouse. Scale bar 50µm. (b) Enumeration of cresyl violet stained motor neurons (>200μm2) in the dorsal horns of the cervical enlargement. Lines in graph are mean values of n=4 mice/group and at least 5 sections/mouse. NS=not significant P=0.1633 Student’s two-tailed unpaired t-test. Scale bar 100µm. (c) Enumeration of VAChT+ motor neurons in the ventral horns of the spinal cord. Representative images are taken from the lumbar enlargement. Lines are mean values of n= 4, 3, 4 mice and at least 4 sections/mouse. * P= 0.0354 (cervical) and * P=0.0487 ** P=0.0034 (lumbar) 1-way ANOVA Dunnett’s Multiple Comparison test. Scale bar 200μm. (d) Hematoxylin and eosin staining visualizing lesions in the thalamus in end stage KO→DTA mice. Lesions were quantified based on the presence of giant cells (white arrow) with an area >150µm2. Lines are mean values of n=3 mice/group and 2 sections/mouse. Scale bar 100µm (top panel) and 25µm (bottom panel). (e) F4/80 and fluoromyelin staining in the thalamus. Images are representative of n=3 mice/group. Scale bar 500µm and 50µm. (f) Confocal images of F4/80 and fluoromyelin staining in the thalamus. Images are representative of n=3 mice/group. Scale bar 10µm.
Supplementary Figure 4 Loss of Tgfbr2 in CX3CR1+ macrophages after niche colonization leads to onset of motor phenotype.
(a) Experimental setup of Cx3cr1CreER/+Tgfbr2fl/fl→DTR chimeras. DTR mice were given TAM (two doses, 48h apart) to recombine CNS-resident microglia, followed by irradiation and bone marrow transplantation (BMT) from Tgfbr2fl/fl or Cx3cr1CreER/+Tgfbr2fl/fl donors one week later. After reconstitution 6 weeks later, mice were given DT to deplete microglia. Tgfbr2 expression was targeted in repopulated CX3CR1+ monocyte-derived macrophages 3 weeks later by TAM administration. (b) Clinical score assessing motor symptoms on the indicated days after TAM. Values in plot are mean±s.e.m. of n=4 and 5 mice. The experiment was performed once. (c) 4-paw hanging wire test to assess grip strength performed at onset of motor symptoms (day 20 after TAM). Lines are mean values of n=4 and 5 mice. ** P=0.0032. Student’s two-tailed unpaired t-test. (d) Analysis of CNS by flow cytometry at day 46 (end stage). Top panel gated on CD11b+CD45+Ly6C–. The data is representative of n=2 mice/group. (e) Kinetic analysis of the transformation of monocyte-derived macrophages after TAM. Gated on CD11b+CD45+Ly6C–Ly6G–F4/80hi. Lines in graphs are mean values of n=2, 2, 2, 3 mice.
Supplementary Figure 5 Loss of Tgfbr2 in CNS-resident microglia leads to slowly progressing motor disease.
(a) qRT-PCR analysis of sorted Ly6C–CD11b+F4/80low (Tgfbr2fl/fl) and Ly6C–CD11b+F4/80hi (Cx3cr1CreER/+Tgfbr2fl/fl) microglia day 7 after TAM. Deletion of Tgfbr2 was assessed by the expression of the floxed exon 2 divided by the unfloxed exon 1. n=2 samples/group sorted from pools of 1-5 mice/sample. (b) CNS analysis by flow cytometry 7 days after TAM. Top panel is gated on live, singlet and Ly6C–Ly6G– cells. Dot plots are representative of three independent experiments. (c-d) Immunofluorescence for (c) F4/80 and Iba-1 or (d) P2ry12 in cortex day 7 after TAM. Images are representative of n=3mice/group. Scale bar 100μm. (e) Confocal images of one Iba-1+ microglial cell in the cortex to visualize morphology. Images are representative of n=3 mice/group. Scale bar 10μm. (f) CNS analysis of head-protected CD45.1→Cx3cr1CreER/+Tgfbr2fl/fl chimeras analyzed 3 weeks after TAM administration. Top panel is gated on live, singlet and Ly6C–Ly6G– cells. Values in plots are mean±s.d. of n=7 and 6 mice. The experiment was performed once. (g-h) Development of motor symptoms in n=7 Tgfbr2fl/fl and n=6 Cx3cr1CreER/+Tgfbr2fl/fl mice. (g) 4-paw hanging wire test to assess grip strength (max time 180 sec) performed on the indicated days after TAM. Lines represent mean values. (h) Clinical score assessing motor symptoms. Values are mean±s.e.m. The experiment was performed once. (i) Time course analysis of MHCII surface expression on CD11b+CD45+Ly6C–Ly6G– microglia on the indicated days after TAM. Lines represent mean values of n=15, 3, 8, 3 mice.
Supplementary Figures 1–5
Top 20 predicted upstream regulators of the differentially expressed gene set between Tgfbr2–/– macrophages and WT macrophages, using Ingenuity Pathway Analysis. n=3 samples/group from 2-4 pooled mice/sample. Overlap p-values are calculated using Fisher’s exact test and P<0.01 are considered significant
Free movement of Tgfbr2fl/fl→DTA chimeric mice day 21 after TAM administration. The video is representative of n=17 mice from three independent experiments
Free movement of Cx3cr1CreER/+Tgfbr2fl/fl→DTA chimeric mice day 21 after TAM administration. The video is representative of n=26 mice from three independent experiments
4-paw hanging-wire trial day 10 after TAM administration in Tgfbr2fl/fl→DTA chimeras. The video is representative of n=7 mice. The experiment was repeated from a greater height in which all mice remained suspended for 180 seconds (included in Figure 2c)
4-paw hanging-wire trial day 10 after TAM administration in Cx3cr1CreER/+Tgfbr2fl/fl→DTA chimeras. The video is representative of n=11 mice. The experiment was repeated from a greater height
Video of Cx3cr1CreER/+Tgfbr2fl/fl→DTA chimeric mice at end stage (day 32-40 after TAM). Of 19 mice in two independent experiments that were followed long-term for symptoms, 15 reached the end stage within 40 days of TAM administration